Promega Executive and Leadership Team

Deanna Schuppel, the Senior Executive Administrator, Chief Executive Officer at Promega, provides critical administrative support and operational oversight directly to the Chief Executive Officer. This role ensures the seamless functioning of executive-level operations, managing complex schedules and facilitating communication across key departments. Schuppel's responsibilities include coordinating executive meetings, preparing essential documentation, and acting as a liaison between the CEO's office and other stakeholders. The strategic alignment of administrative functions under Schuppel's purview directly supports Promega's mission to advance scientific discovery. This leadership position is vital for maintaining executive efficiency and enabling the CEO to focus on overarching company strategy and market impact. Deanna Schuppel's contribution is essential for the smooth execution of high-level corporate initiatives.

William Linton, the Chairman, Chief Executive Officer & President at Promega, architects the company's long-term vision and strategic direction. Linton guides Promega's global operations, driving innovation in biotechnology and molecular biology products. His leadership encompasses overseeing the company's extensive portfolio, which spans genomics, protein analysis, cellular analysis, drug discovery, and genetic identity. Linton's role involves fostering a culture of scientific advancement and ensuring Promega's continued impact on research and development worldwide. The Chairman, Chief Executive Officer & President directs corporate strategy, ensuring alignment with market needs and scientific progress. William Linton's executive decisions shape Promega's market position and its contribution to scientific breakthroughs, solidifying the company's commitment to empowering researchers and improving human health.

Chris Yarbro, the Chief Financial Officer at Promega, manages the company's financial operations and strategic fiscal planning. Yarbro oversees all aspects of financial reporting, budgeting, and investment, ensuring Promega's fiscal health and sustainable growth. This executive position is crucial for guiding financial strategies that support the company's extensive research and development initiatives in genomics, protein analysis, and drug discovery. The Chief Financial Officer ensures compliance with financial regulations and optimizes resource allocation across global operations. Chris Yarbro's financial acumen directly contributes to Promega's ability to innovate and expand its market reach, reinforcing the company's commitment to scientific advancement and market leadership. This role is fundamental to Promega's operational stability and strategic expansion.

Kristen Yetter, the General Manager and President at Promega, directs significant operational segments and drives business growth within assigned areas. Yetter oversees the execution of strategic plans, ensuring operational efficiency and market responsiveness across key business units. This leadership role is essential for translating Promega's scientific advancements in genomics, protein analysis, and cellular analysis into tangible market outcomes. The General Manager and President manages cross-functional teams to achieve performance targets and foster innovation. Kristen Yetter's leadership ensures that Promega's operational framework effectively supports its mission to empower scientific discovery and improve human health, contributing significantly to the company's overall success and market presence.

Sandra Gardner, the Chief Information Officer at Promega, directs the company's global information technology strategy and infrastructure. Gardner oversees the development and implementation of robust digital solutions that support Promega's extensive product portfolio in genomics, protein analysis, and cellular analysis. This leadership role is critical for ensuring data integrity, cybersecurity, and the efficient operation of all IT systems across the organization. The Chief Information Officer ensures that technology investments align with Promega's business objectives, facilitating scientific discovery and drug development. Sandra Gardner's expertise drives technological innovation, enhancing operational efficiency and supporting the company's mission to empower researchers. This executive function is paramount for maintaining Promega's competitive edge in the biotechnology sector.

Kara Machleidt, the Global Chief Revenue Officer, Strategic Business Lead at Promega, drives revenue generation and strategic business development across global markets. Machleidt oversees sales operations, market expansion initiatives, and key partnership development, ensuring Promega's products reach researchers worldwide. This leadership role is instrumental in translating Promega's scientific innovations in genomics, protein analysis, and cellular analysis into market success. The Global Chief Revenue Officer, Strategic Business Lead aligns sales strategies with corporate objectives, focusing on expanding market share and enhancing customer relationships. Kara Machleidt's strategic vision and revenue leadership are critical for Promega's sustained growth and its ability to support advancements in biotechnology and drug discovery. This executive function ensures market penetration and commercial success.

Ash Anderson, the Chief Medical Officer at Promega, provides critical medical and scientific expertise to guide the company's product development and strategic initiatives. Anderson oversees the clinical relevance and application of Promega's biotechnology tools, particularly in areas like cellular analysis and drug discovery. This role ensures that Promega's offerings align with current medical research needs and regulatory standards. The Chief Medical Officer contributes to the scientific integrity of Promega's portfolio, fostering collaborations with healthcare and research institutions. Ash Anderson's medical insights are vital for enhancing the impact of Promega's products on human health and scientific understanding, reinforcing the company's commitment to advancing life sciences. This executive position bridges scientific innovation with clinical application.